WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
After a successful feasibility study, Company expands into the high growth biopesticide sector with a funded research and development program to produce valuable natural ingredients using its precision fermentation platform Program expected to generate over $2 million in revenue in first year with guaranteed payments of over $1 million in 2024 Company now anticipates revenue […]
WILLOW BIOSCIENCES ANNOUNCESANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
Sunnyvale, California – July 26, 2024 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on July 26, 2024 (the “Meeting“). A total of 27,685,611 common shares, representing approximately 21.74% of the Company’s issued and outstanding shares […]
WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES Calgary, Alberta – July 18, 2024 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce that it has closed its previously announced brokered […]
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM
Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients Company anticipates revenue of over $1.0 million in Q2, and over $3.5 million for 2024 on existing programs Company expands its AI platform with the appointment of AI expert and industry veteran Dr. Richard Fox as Senior Advisor, AI Platform […]
WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERINGTO RAISE UP TO $3.0 MILLION
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Sunnyvale, California – June 3, 2024 – Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a brokered private placement offering (the “Offering”) of up […]
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
Collaboration provides Laurus access to Willow’s AI-driven bioengineering platform The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredients, including Willow’s corticosteroid programs The agreement with Laurus is the largest collaboration agreement Willow has signed to date Sunnyvale, California – May 30, 2024 – Willow Biosciences Inc. (“Willow“) (TSX: WLLW) (OTCQB: CANSF), a […]